Aceso Therapeutics
PrivateLast Round
Grant
Aug 12, 2026
Total Funding Raised
$1.11M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Aceso Therapeutics operates in Healthcare & Life Sciences and is based in Montpellier. Its latest recorded funding round was a Grant round in August 2026.
Aceso Therapeutics is a biotechnology company developing novel RNA-based therapies, including its lead candidate ACT-101, for the treatment of cystic fibrosis and other respiratory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aceso Therapeutics Comparables
Compare Aceso Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SpliSense | 82% | |
| Spirovant Sciences | 81% | |
| Sanofi | 76% |
For institutional investors. Book with your work email.
Aceso Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 12, 2026 | ||||
| Accelerator | Mar 1, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aceso Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agence Nationale de la Recherche | Grant |
| SATT AxLR | Grant, Accelerator |
| Bpifrance | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 12, 2026
Received grant funding from Bpifrance.
- Mar 1, 2026
Received funding from SATT AxLR.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 8, 2026
On Sep 7th '26, Aceso Therapeutics and Aptar announce a collaboration to advance Aceso's ACT-101 inhaled antisense oligonucleotide therapy for cystic fibrosis, with the program supporting inhaled formulation development and device assessment.
- is_developingSep 8, 2026
Aceso Therapeutics is developing the antisense oligonucleotide ACT-101 to target disease mechanisms associated with cystic fibrosis and plans to explore inhaled lung delivery, while Nanopharm leads formulation development and device assessment.
- partners_withSep 7, 2026
On Sep 7th '26, Aceso Therapeutics partners with Nanopharm to advance ACT-101, an inhaled antisense oligonucleotide candidate for cystic fibrosis, through formulation development and device assessment toward clinical evaluation.
For institutional investors. Book with your work email.
Aceso Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aceso Therapeutics's valuation, stock price, and market status.
Is Aceso Therapeutics a public or private company?
Aceso Therapeutics is a private company.
What is the current stock price of Aceso Therapeutics?
Aceso Therapeutics is a private company, so its shares have no public market price. Caplight tracks Aceso Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aceso Therapeutics worth (valuation)?
Valuation information for Aceso Therapeutics is not publicly available.
Can I buy Aceso Therapeutics stock?
Aceso Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aceso Therapeutics's last funding round?
Aceso Therapeutics's most recent funding round was Grant on August 12, 2026.
Who are the main investors in Aceso Therapeutics?
Key investors in Aceso Therapeutics include SATT AxLR.
Will Aceso Therapeutics IPO soon?
No public IPO plans have been announced for Aceso Therapeutics.
How can I track Aceso Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Aceso Therapeutics's shares on secondary markets.